An eight week, double-blind, placebo controlled, adjunctive study of the primary effects of the use of flexible doses of modafinil 50mg to 200mg, on the negative symptoms, cognition, and excessive daytime sleepiness in schizophrenic patients

Trial Profile

An eight week, double-blind, placebo controlled, adjunctive study of the primary effects of the use of flexible doses of modafinil 50mg to 200mg, on the negative symptoms, cognition, and excessive daytime sleepiness in schizophrenic patients

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Feb 2009

At a glance

  • Drugs Modafinil (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Feb 2009 Actual end date (Feb 2008) added as reported by ClinicalTrials.gov.
    • 20 Feb 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 31 Oct 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top